Photo by hudsoncrafted from unsplash
Patel and colleagues report the results of the basket trial (DART) studying the checkpoint inhibitors combination, ipilimumab plus nivolumab, in a cohort of patients with neuroendocrine neoplasms (NEN; ref. [1][1]).… Click to show full abstract
Patel and colleagues report the results of the basket trial (DART) studying the checkpoint inhibitors combination, ipilimumab plus nivolumab, in a cohort of patients with neuroendocrine neoplasms (NEN; ref. [1][1]). We commend the authors for their efforts enrolling patients with such an uncommon
Keywords:
s1609 neuroendocrine;
neuroendocrine letter;
rare tumors;
ipilimumab nivolumab;
tumors s1609;
nivolumab rare
Journal Title: Clinical Cancer Research
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cancer Research
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!